We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-13.06%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$1.87B
AUM Growth
-$516M
Cap. Flow
-$33.5M
Cap. Flow %
-1.79%
Top 10 Hldgs %
48.99%
Holding
144
New
7
Increased
8
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$45.3M
2
FATE icon
Fate Therapeutics
FATE
+$16.6M
3
CYTK icon
Cytokinetics
CYTK
+$11.1M
4
SNTI icon
Senti Biosciences Holdings
SNTI
+$4.46M
5
WVE icon
Wave Life Sciences
WVE
+$3.85M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$60.4M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$18.9M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$18M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.9M
5
BLU
BELLUS Health Inc.
BLU
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 89.18%
2 Consumer Discretionary 5.28%
3 Financials 0.87%
4 Consumer Staples 0.28%
5 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SDGR icon
26
Schrodinger
SDGR
$1.13B
$18.5M 0.99%
700,000
– –
GBIO
27
DELISTED
Generation Bio
GBIO
$18.5M 0.99%
281,419
– –
ERAS icon
28
Erasca
ERAS
$6.15B
$17.7M 0.94%
3,172,221
– –
DNLI icon
29
Denali Therapeutics
DNLI
$3.79B
$17.7M 0.94%
600,000
– –
REPL icon
30
Replimune Group
REPL
$454M
$15.7M 0.84%
900,000
– –
SAGE
31
DELISTED
Sage Therapeutics
SAGE
$14.5M 0.78%
450,000
-300,000
-40% -$10.1M
NTLA icon
32
Intellia Therapeutics
NTLA
$1.51B
$14.2M 0.76%
275,000
– –
EVO icon
33
Evotec
EVO
$686M
$13.8M 0.74%
1,149,425
– –
RLAY icon
34
Relay Therapeutics
RLAY
$4B
$11.7M 0.63%
700,000
– –
MRSN
35
DELISTED
Mersana Therapeutics
MRSN
$10.2M 0.54%
88,000
– –
AUPH icon
36
Aurinia Pharmaceuticals
AUPH
$1.95B
$10.1M 0.54%
1,000,000
– –
RPTX
37
DELISTED
Repare Therapeutics
RPTX
$9.79M 0.52%
700,000
– –
WVE icon
38
Wave Life Sciences
WVE
$1.12B
$9.75M 0.52%
3,000,000
+2,000,000
+200% +$3.85M
NBP
39
NovaBridge Biosciences American Depositary Shares
NBP
$186M
$9.61M 0.51%
850,000
– –
TRML
40
DELISTED
Tourmaline Bio
TRML
$9.31M 0.5%
206,426
– –
KLRS
41
Kalaris Therapeutics
KLRS
$80.9M
$9.06M 0.48%
101,016
– –
OMGA
42
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$8.64M 0.46%
2,273,530
– –
ITOS
43
DELISTED
iTeos Therapeutics
ITOS
$8.24M 0.44%
400,000
– –
ATRA icon
44
Atara Biotherapeutics
ATRA
$72.6M
$7.79M 0.42%
40,000
– –
OMEG
45
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$7.39M 0.39%
750,000
– –
IMA
46
ImageneBio Inc
IMA
$63.4M
$6.86M 0.37%
129,126
– –
RNAC icon
47
Cartesian Therapeutics
RNAC
$218M
$6.4M 0.34%
162,773
+29,440
+22% +$873K
VERV
48
DELISTED
Verve Therapeutics
VERV
$6.11M 0.33%
400,000
– –
YMAB
49
DELISTED
Y-mAbs Therapeutics
YMAB
$6.05M 0.32%
400,000
– –
EXAI
50
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$5.99M 0.32%
550,000
– –
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2022 Portfolio in Review

As of Q2 2022, Artal Group held 144 positions worth $1.87B, down 22% from $2.39B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Artal Group's Q2 2022 filing shows 7 new, 8 increased, 8 reduced and 9 closed positions. Its largest new stake was CinCor Pharma, Inc. Common Stock: 137,010 shares worth $2.58M. The largest sale was argenx, an estimated $60.4M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 91% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Artal Group's largest Q2 2022 buy was CinCor Pharma, Inc. Common Stock: 137,010 shares worth $2.58M.
  • Artal Group added most to Scholar Rock in Q2 2022, an estimated $45.3M increase.
  • Artal Group's biggest Q2 2022 reduction was argenx, cutting an estimated $60.4M.
  • Artal Group fully exited Protagonist Therapeutics in Q2 2022, selling an estimated $18.9M.
  • Artal Group's ten largest holdings make up 49% of its $1.87B portfolio in Q2 2022.
  • Artal Group opened 7 new positions and closed 9 in Q2 2022.
  • Artal Group's portfolio value fell 22% quarter-over-quarter to $1.87B.

Based on Artal Group's 13F filing for Q2 2022, filed 11 Aug 2022.